Skip to content
2000
Volume 22, Issue 9
  • ISSN: 1389-2037
  • E-ISSN: 1875-5550

Abstract

The moonlighting protein, Prdx-6, exhibits peroxidase activity, phospholipase activity, and lysophosphatidylcholine acyltransferase (LPCAT) activity. Although it is ubiquitous in expression, its level is prominently high in the lung. Prdx-6 has been known to be an important enzyme for the maintenance of normal lung physiologies including, anti-oxidant defense, lung surfactant homeostasis, and cell signaling. Studies further unveiled that the altered activity (peroxidase or ai- PLA2) of this enzyme is linked with various lung pathologies or diseases. In the present article, we attempted to address the various pathophysiologies or disease conditions (like lung ischemia, hyperoxia, lung cancer, emphysema, and acute lung injury) wherein Prdx-6 is involved. The study implicates that Prdx-6 could be used as a common drug target for multiple lung diseases. Important future insights have also been incorporated.

Loading

Article metrics loading...

/content/journals/cpps/10.2174/1389203722666211109101853
2021-09-01
2025-09-04
Loading full text...

Full text loading...

/content/journals/cpps/10.2174/1389203722666211109101853
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test